Key statistics
On Tuesday, Phathom Pharmaceuticals Inc (PHAT:NSQ) closed at 12.82, -29.98% below its 52-week high of 18.31, set on Dec 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 13.00 |
|---|---|
| High | 13.07 |
| Low | 12.74 |
| Bid | 12.70 |
| Offer | 13.46 |
| Previous close | 12.78 |
| Average volume | 800.16k |
|---|---|
| Shares outstanding | 77.92m |
| Free float | 73.83m |
| P/E (TTM) | -- |
| Market cap | 995.79m USD |
| EPS (TTM) | -3.81 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
- Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
- Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
- Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
- Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
- Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
- Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
- Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
More ▼
